Back to today’s briefing

Story perspectives

Nordea Boosts Myriad Genetics Stake Amid Cancer Study

1/11/2025

41 10

Summary

Story summary

Nordea Investment Management has ramped up its investment in Myriad Genetics, boosting its stake by an impressive 117% to 332,913 shares worth $4.5 million. In an exciting collaboration, the University of Texas MD Anderson Cancer Center has joined forces with Myriad for a groundbreaking five-year study on its MRD assay across multiple cancers. Analysts maintain a "Hold" rating for Myriad, with a target price of $24.27.

1 of 1

Story summary

Nordea Investment Management has ramped up its investment in Myriad Genetics, boosting its stake by an impressive 117% to 332,913 shares worth $4.5 million. In an exciting collaboration, the University of Texas MD Anderson Cancer Center has joined forces with Myriad for a groundbreaking five-year study on its MRD assay across multiple cancers. Analysts maintain a "Hold" rating for Myriad, with a target price of $24.27.